Improved Survival After Multimodal Approach with I Treatment in Patients with Bone Metastases Secondary to Differentiated Thyroid Cancer.

The objective of this study was to evaluate the overall survival (OS) of radioiodine (I) treatments alone or combined with non-I treatments in patients with bone metastases (BM) of differentiated thyroid cancer (DTC). This was a retrospective study of patients who were evaluated between 2001 and 2018 at MedStar Washington Hospital Center and who had DTC, BM, and at least one I treatment after the diagnosis of BM. The OS was analyzed by Kaplan-Meier survival curves and was compared by log-rank test between two groups: patients who received I treatments alone and those who received treatments combining I with non-I treatments (CombTx).